Proyectos de ley › 89.ª Asamblea General
HSB 623
Dónde está ahora
- Hecho: Presentado24 de enero de 2022
- Hecho: Subcomité27 de enero de 2022
- Hecho: Comité de la Cámara9 de febrero de 2022
- Se saltó: Lo aprueba la CámaraSigue como HF 2384
- Sigue: Comité del Senado
- Sigue: Lo aprueba el Senado
- Sigue: A gobernador(a)
- Sigue: Firmado como ley
Ahora es HF 2384 → Sigue avanzando con el número nuevo. Ir a HF 2384 ¿Qué es el embudo (funnel)?
Qué contiene
Resumen con IA This bill changes how pharmacy benefits managers, insurance companies, and pharmacies work together regarding prescription drugs. It requires these companies to act in the best interest of health insurance providers and the people they cover. The rules also prevent companies from discriminating against pharmacies and ensure patients can access lower-cost drug options and choose where they fill their prescriptions. (Todavía no está traducido al español.)1
Lea la explicación oficial (en inglés)
This bill relates to pharmacy benefits managers (PBM), pharmacies, and prescription drug benefits. The bill provides that a PBM owes a fiduciary duty to each health carrier (carrier) for whom the PBM manages a prescription drug benefit (drug benefit) provided by the carrier, and shall discharge its duties in accordance with applicable state and federal law. The bill also provides that a carrier shall owe a fiduciary duty to each covered person participating in a health benefit plan (benefit plan) offered or issued by the carrier, and the carrier shall discharge its duties in accordance with applicable state and federal law. The bill prohibits a PBM, carrier, or benefit plan from discriminating against a pharmacy or pharmacist with respect to participation, referral, reimbursement of a covered service, or indemnification if a pharmacist is acting within the scope of the pharmacist’s license. The bill requires a PBM to allow a pharmacy located in the state to participate in a pharmacy network (network) provided that the pharmacy accepts the same terms and conditions as the PBM imposes on the pharmacies in the network. “Pharmacy benefits manager” is defined in the bill as a person who, pursuant to a contract or other relationship with a carrier, either directly or through an intermediary, manages a drug benefit provided by the carrier. “Pharmacy network”, “pharmacist”, “pharmacy”, “prescription drug benefit”, and “health carrier” are also defined in the bill. The bill prohibits a PBM from assessing, charging, or collecting any form of remuneration that passes from a pharmacy in the network to the PBM including but not limited to claim processing fees, performance-based fees, network participation fees, or accreditation fees. The bill prohibits a covered person from being required to make a cost-sharing payment at the point-of-sale for a prescription drug (drug) in an amount that exceeds the maximum allowable cost (MAC) for that drug. _____ as the maximum amount that a pharmacy will be reimbursed by a PBM or a carrier for a generic drug, brand-name drug, biologic product, or other drug and that may include the average or national average acquisition cost; the average manufacturer price; the average wholesale price; the brand or generic effective rate; discount indexing; federal upper limits; wholesale acquisition cost; or any other term used by a PBM or carrier to establish reimbursement rates for a pharmacy. “Covered person” is defined in the bill. A PBM cannot prohibit a pharmacy from disclosing the availability of a lower-cost drug option to a covered person, or from selling a lower-cost drug option to a covered person. The bill requires that any amount paid by a covered person for a drug in the circumstances detailed in the bill must be applied to any deductible imposed by the covered person’s health benefit plan in accordance with the plan’s coverage documents. Under the bill, a covered person cannot be prohibited from filling a drug order at any pharmacy located in the state if the pharmacy accepts the same terms and conditions as the covered person’s benefit plan. A PBM cannot impose different cost-sharing or additional fees on a covered person based on the pharmacy at which a covered person fills their prescription. A PBM cannot require a covered person, as a condition of payment or reimbursement, to purchase pharmacy services, including drugs, exclusively through a mail-order pharmacy. The bill requires that a covered person’s cost-sharing for a drug shall be calculated at the point-of-sale based on a price that is reduced by an amount equal to at least 100 percent of all rebates that have been received, or that will be received, by the health carrier or a PBM in connection with the dispensing or administration of the drug. A health carrier may decrease a covered person’s cost-sharing by a greater amount. “Rebate” is defined in the bill. _____ calculating the covered person’s total contribution toward the covered person’s cost-sharing. “Cost-sharing” is defined in the bill. The bill allows a pharmacy to decline to dispense a drug to a covered person if, as a result of the maximum allowable cost list (MACL) to which the pharmacy is subject, the pharmacy will be reimbursed less than the pharmacy’s acquisition cost. “Pharmacy acquisition cost” is defined in the bill. “Maximum allowable cost list” is defined in the bill as a list of prescription drugs that includes the MAC for each drug and that is used, directly or indirectly, by a PBM. “Pharmacy acquisition cost” is also defined in the bill. The bill requires that prior to placement of a particular drug on a MACL, a PBM must ensure that the drug is listed as therapeutically and pharmaceutically equivalent in the most recent edition of the “Approved Drug Products with Therapeutic Equivalence Evaluations”, published by the United States food and drug administration; the drug cannot be obsolete or temporarily unavailable; and the drug must be available for purchase by all pharmacies in the state from a national or regional wholesale distributor that is licensed in the state. “Wholesale distributor” is defined in the bill. The bill requires a PBM to provide each pharmacy in a network reasonable access to the MACL to which the pharmacy is subject, and to update each MACL within seven calendar days from the date of an increase of percent or more in the pharmacy acquisition cost of a drug by one or more wholesale distributors doing business in the state. The PBM must also update a MACL within seven calendar days from the date of a change in the methodology, or a change in a value of a variable applied in the methodology, on which the MACL is based. The PBM is also required to provide a process for each pharmacy in a network to receive prompt notice of all changes to a MACL. _____ the drug is administered or dispensed. In addition to the reimbursement, a PBM shall reimburse the pharmacy or pharmacist a professional dispensing fee that is no less than the pharmacy dispensing fee published in the Iowa Medicaid enterprise provider fee schedule on the date that the drug is administered or dispensed. The bill prohibits a PBM from reimbursing a pharmacy located in the state in an amount less than the amount that the PBM reimburses a PBM affiliate for dispensing the same drug as the pharmacy. “Pharmacy benefits manager affiliate” is defined in the bill. The bill provides that after the date of receipt of a clean claim submitted by a pharmacy, a PBM cannot retroactively reduce payment on the claim, either directly or indirectly, except if the claim is found not to be a clean claim during the course of a routine audit. “Clean claim” is defined in the bill. The bill requires a PBM to provide a process for pharmacies to appeal a MAC, or a reimbursement made under a MACL. The requirements for the appeal process are detailed in the bill. The commissioner of insurance (commissioner) is required to take any enforcement action under the commissioner’s authority to enforce compliance with the bill.7, and may suspend or revoke a PBM’s certificate of registration as a third-party administrator upon a finding that the PBM violated any requirements of the bill, or any applicable requirements pertaining to third-party administrators under Code chapter 510. A PBM is subject to the commissioner’s authority to conduct an examination pursuant to Code chapter 507 and a proceeding pursuant to Code chapter 507B. A PBM is also subject to the commissioner’s authority to conduct an examination, audit, or inspection pursuant to Code chapter 510. _____ commissioner conducts an examination, a proceeding, an audit, or an inspection, all information received from the PBM, and all documents related to the examination, proceeding, audit, or inspection are confidential records pursuant to Code chapter 22.4, for which the commissioner may issue an order or impose a penalty. The bill requires the commissioner to adopt rules to administer the bill. If a provision of the bill or its application to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of the bill that can be given effect without the invalid provision or application.9.10 (enforcement). The bill applies to PBMs that manage a health carrier’s prescription drug benefit in the state on or after the effective date of the bill.
Cambiado después por las enmiendas S-5182, S-5158, H-8260, H-8198; vea Enmiendas.
Texto completo del proyecto (en inglés) · Qué cambió antes de aprobarse2
House subcommittee
Named January 27, 2022. On February 8, 2022 it recommended passage. Vote Total: 3-0.
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part
Nota fiscal
Resumen con IA This bill changes rules for pharmacy benefits managers regarding drug reimbursements and how much people pay at the pharmacy. It is estimated that expenditures from the Commerce Revolving Fund will increase by $200,000 annually to fund two new full-time positions for the Iowa Insurance Division. (en inglés)3
Lea la nota fiscal (en inglés)
Description
House File 2384 relates to pharmacy benefits managers (PBMs), pharmacies, and prescription drug benefits. The Bill makes the following changes:
- Division I defines terms, requires rulemaking, clarifies language, adds additional duties to PBMs and the Iowa Insurance Division (IID) in the Department of Commerce, and makes changes to PBM reimbursements.
- Prohibits a covered person from making a cost-sharing payment at the point of sale for a prescription drug that exceeds the total amount that the pharmacy, at which the covered person’s prescription drug order is reimbursed, paid.
- Prevents PBMs from prohibiting pharmacies from disclosing or selling lower-cost drug options to covered persons.
- Requires a PBM to reimburse all in-state pharmacies at the rate the PBM reimburses its affiliates for dispersing the same prescription drug.
- Division II defines terms and changes references to “health carrier” in Iowa Code section 510C.2 to “third-party payor.”
- Division III permits the IID to adopt emergency rules to implement the provisions of the Bill. The rules shall be immediately effective unless otherwise specified.
Background
Cost-sharing payments are out-of-pocket cost obligations imposed by a health benefit plan on a covered person. These include but are not limited to coverage limits, copayments, coinsurance, and deductibles.
The Commissioner of Insurance is responsible for ensuring parties subject to laws related to cost-sharing payments law are in compliance.
House File 2384 is estimated to impact approximately 25.8% of the population (822,000). This includes individual coverage, fully insured small and large employer groups, self-insured public employees, and the State of Iowa Plan.
Of the population covered by insurance plans not regulated by Iowa law, approximately 45.2% are covered by government-sponsored health insurance, 23.0% are covered by employer coverage that is governed by the federal Employee Retirement Income Security Act of 1974 (ERISA), and the remaining 6.0% are uninsured. Table 1 below details the population covered by insurance plans regulated by Iowa law.
Table 1 — Population Covered by Insurance Plans Regulated by Iowa Law Source: Iowa Insurance Division, Department of Commerce
Assumption
Additional examination and enforcement actions carried out by the Iowa Insurance Division will require the Division to add 2.0 full-time equivalent (FTE) positions for an Insurance Market Complaint Analyst and an Insurance Compliance Analyst.
Fiscal Impact
Expenditures from the Commerce Revolving Fund are estimated to increase by $200,000 annually for 2.0 FTE positions. This cost is for an Insurance Market Complaint Analyst FTE position to process complaints as received, with a total cost of approximately $110,000, and an Insurance Compliance Analyst FTE position, with a total cost of approximately $90,000, for the purposes of examining and enforcing compliance with the provisions of the Bill.
Sources
- Board of Regents
- Iowa Insurance Division, Department of Commerce
- Wellmark
- Final Fiscal Note — Pharmacy Benefits Managers · 27 de junio de 2022 · $110,000
- Pharmacy Benefits Managers · 5 de mayo de 2022
- Pharmacy Benefits Managers · 5 de abril de 2022
- Pharmacy Benefits Managers · 1 de marzo de 2022
- Pharmacy Benefits Managers · 1 de marzo de 2022
Lo que cambia del Código de Iowa (Iowa Code)
Crea§510B.11§510B.12§510B.8A§510B.8B§510B.8C§510B.8D§510B.8E
Modifica§505.26§507B.4§510B.1§510B.10§510B.4§510B.5§510B.6§510B.7§510B.8§510B.9
Deroga§510B.3
Cabildeo
15 a favor · 22 en contra · 20 indecisos · Quiénes →
Family tree
Study bill
Similar bills
- HF 729 Relating to pharmacy benefits managers, pharmacies, and prescription drug benefits, and in…89th General Assembly · Approved by committeeSimilar
Matched by wording or an identical title.